Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
R-Pharm US
NJ - Princeton
POSACONAZOLE (posaconazole) by R-Pharm US is 12. Approved for invasive aspergillus, such, those with hematologic malignancies with prolonged neutropenia from chemotherapy and 2 more indications. First approved in 2023.
Drug data last refreshed 22h ago
12.1 Mechanism of Action Posaconazole is an azole antifungal agent [see ] . 12.2 Pharmacodynamics Exposure Response Relationship Prophylaxis: In clinical studies of neutropenic patients who were receiving cytotoxic chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes…
Worked on POSACONAZOLE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Azole Antifungal
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
Pharmacokinetic of Posaconazole in Critically Ill Patients
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo